

# Heparanase - Pipeline Review, H2 2020

<https://marketpublishers.com/r/H4DEEA21FFADEN.html>

Date: September 2020

Pages: 58

Price: US\$ 3,500.00 (Single User License)

ID: H4DEEA21FFADEN

## Abstracts

Heparanase - Pipeline Review, H2 2020

### SUMMARY

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

The latest report Heparanase - Pipeline Review, H2 2020, outlays comprehensive information on the Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -

Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM).

Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Retinopathy, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head

And Neck Cancer, Inflammation, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor and Wet (Neovascular/Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

The report reviews Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects

The report assesses Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Overview

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -  
Companies Involved in Therapeutics Development

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Leadiant Biosciences Inc

Momenta Pharmaceuticals Inc

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Zucero Therapeutics Ltd

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug  
Profiles

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone  
Marrow Transplant Rejection and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-2180 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-30119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

necuparanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pixatimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roneparstat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -

Dormant Products

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) -

Discontinued Products

Heparanase (Endo Glucuronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Products under Development by Companies, H2 2020 (Contd..2), H2 2020  
Products under Development by Companies, H2 2020 (Contd..3), H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by Actavalon Inc, H2 2020  
Pipeline by Active Biotech AB, H2 2020  
Pipeline by Ampio Pharmaceuticals Inc, H2 2020  
Pipeline by AnToIRx Inc, H2 2020  
Pipeline by Bayer AG, H2 2020  
Pipeline by Dermavant Sciences Inc, H2 2020  
Pipeline by Hercules Pharmaceuticals BV, H2 2020  
Pipeline by Hutchison MediPharma Ltd, H2 2020  
Pipeline by Ikena Oncology Inc, H2 2020  
Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020  
Pipeline by Magenta Therapeutics Inc, H2 2020  
Pipeline by Pfizer Inc, H2 2020  
Pipeline by Phenex Pharmaceuticals AG, H2 2020  
Pipeline by Shenogen Pharma Group Ltd, H2 2020  
Pipeline by Sol-Gel Technologies Ltd, H2 2020  
Pipeline by Welichem Biotech Inc, H2 2020  
Dormant Products, H2 2020  
Dormant Products, H2 2020 (Contd..1), H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Leadiant Biosciences Inc

Momenta Pharmaceuticals Inc

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Zucero Therapeutics Ltd



## I would like to order

Product name: Heparanase - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/H4DEEA21FFADEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H4DEEA21FFADEN.html>